Myriad Genetics Inc. held its 2025 Annual Meeting of Stockholders on June 5, 2025. During the meeting, stockholders approved an amendment to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan, increasing the aggregate number of shares of common stock available for grant by an additional 6.5 million shares. The ratification of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025, was approved. Additionally, the election of directors Samraat S. Raha, Heiner Dreismann, PH.D., and Colleen F. Reitan was confirmed.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。